Dan Burrows

Dan Burrows

Dan Burrows is a veteran of CBS MoneyWatch, DailyFinance, SmartMoney and Dow Jones MarketWatch, and has written for The Wall Street Journal, Consumer Reports and other publications. He favors value investing and writes about asset prices and macroeconomic trends for the long-term investor. He holds no individual securities.

Recent Articles

HLF Stock: Herbalife Criminal Probe Makes Bill Ackman’s Day, But…

A criminal probe into Herbalife has HLF stock reeling, but retail investors should still stay away from Bill Ackman's billion-dollar short bet.

5 Can’t-Miss Reports to Put in Your Earnings Calendar

Earnings reports from these key companies could help stop the market selloff -- or spark further declines

5 High-Yield, Large-Cap Dividend Stocks to Buy

REITs and MLPs are great, but it's important to diversify your holdings in high-yield dividend stocks with dependable, straight-up corporate payers, too.

PHOT Suspended by SEC – Sell Your Marijuana Stocks (While You Still Can)

The SEC has halted trading in Growlife (PHOT) over potential securities fraud. Which of the well-known marijuana stocks will be next?

Yes, You SHOULD Kill BlackBerry Phones to Save BBRY

BlackBerry stock is languishing. And with less than 1% of the global market, the best thing to do to help BBRY is pull the plug on BlackBerry phones.

AA Stock — Autos and Airplanes Boost Alcoa

Alcoa is no longer a stodgy aluminum smelter, and now AA stock is going on an incredible run. But here's why you shouldn't jump in just yet.

Berkshire Hathaway: Warren Buffett Still a Market Master

Warren Buffett might be having trouble keeping up with the S&P 500, but that's only because the market won't pay up for Berkshire Hathaway's earnings.

5 Stocks to Buy in April

The technicals say these blue chips are stocks to buy this month thanks to price momentum and seasonal strength. Here's a closer look.

Earnings Season Will Be Ugly, But Prettier Than Expected

Weak corporate earnings won't be good, but given Wall Street's pessimism, they should easily beat expectations this earnings season.

Pharmaceuticals Deals: QCOR Gets a Big Premium, Roche Goes Shopping

Monday's big pharmaceuticals deals included Mallinckrodt buying Questcor for $5.6B -- a 27% premium to QCOR stock -- and Roche picking up Ranbaxy.